The acquisition will be funded through the Initial Public Offer proceeds raised by Senores Pharmaceuticals Limited.

Venus Remedies receives marketing authorization for Sugammadex from Philippines: Our Bureau, Mumbai Tuesday, March 4, 2025, 15:40 Hrs [IST] Venus Remedies Limited, a leading India ...

Venus Remedies receives marketing authorisation for Sugammadex in the Philippines, marking a major step in its expansion into complex generics and the ASEAN market. Sugammadex is a relaxant-binding ...

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Valued at $50 billion, the Indian pharmaceutical sector continues to grow, fueled by cost efficiency, cutting-edge ...

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics ...

In the 10-K report, Amneal Pharmaceuticals disclosed its summarized consolidated cash flows for the years ended December 31, ...

Amneal Pharmaceuticals, Inc. has recently released its 10-K report, providing a comprehensive overview of its business ...

Q4 2024 Earnings Call Transcript February 28, 2025 Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

“There's always going to be somebody who is going to be trying to bring falsified medicines into the marketplace, that's just the way of the world unfortunately” The Falsified Medicines ...

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by ...